Company Overview
Snapshot
Founded in November 2009 by Saher Hamed, M.D., Ph.D., Remedor Biomed operates with 1–10 employees. The company has secured one disclosed funding round and holds a patent, focusing on developing advanced medications for complex skin wounds.
Business overview
Remedor Biomed is a clinical-stage biopharmaceutical company specializing in the development of medications for chronic and complex skin wounds that are unresponsive to conventional treatments. The company's core technology platform utilizes a naturally occurring glycoprotein, erythropoietin, integrated into a proprietary topical biologic hydrogel-matrix. This innovative delivery system is designed to withstand extreme temperature fluctuations and effectively deliver the active substance to the wound bed. Remedor Biomed primarily targets conditions such as diabetic foot ulcers and deep burn wounds within the pharmaceutical and healthcare sectors.
Strategic signal
In September 2018, Remedor Biomed Ltd. was assigned several patents, signaling the company's commitment to protecting its intellectual property and validating its innovative approach to wound healing. This development indicates a strategic focus on leveraging proprietary technology to address unmet medical needs in the biopharmaceutical industry, potentially strengthening its market position and attracting further investment.
Log in to access full profile ›Company Intelligence Q&A
- When was Remedor Biomed founded?
- Remedor Biomed was founded in November 2009.
- Who founded Remedor Biomed?
- Remedor Biomed was founded by Saher Hamed, M.D., Ph.D.
- What is Remedor Biomed's primary focus?
- Remedor Biomed focuses on developing medications for skin wounds that do not respond well to current treatment options, particularly complex wounds like diabetic foot ulcers and deep burn wounds.
- Has Remedor Biomed received any grants?
- In December 2009, Remedor Biomed received a grant from the Israel Innovation Authority.
- What is Remedor Biomed's core technology?
- Remedor Biomed's core technology platform is based on a formulation containing a naturally occurring glycoprotein, erythropoietin, delivered via a proprietary topical biologic hydrogel-matrix designed for effective substance delivery to the wound bed.